Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
Ongoing Phase 1b study progressing in US and EU for ELA026 in sHLH, a life-threatening inflammatory disease Preclinical data demonstrate ELA026 proof-of-mechanism of SIRP targeting and depletion of pathological immune cells that drive sHLH Company also presents results of sHLH natural history study SOUTH SAN FRANCISCO, CA, December 12, 2022 – Electra Therapeutics, Inc., a clinical […]
